Evidence map›Paper›PMID 38020179›Full record

ArticleFrontiers in medicine2023

Targeted IFNγ induction by a genetically engineered

Zhan Hua, Shan Wu, Yulian Zhang, Xiuhong Wang, Ju Cui, Yunxuan Li, Chengcheng Yang, Min Zhai, Bo Deng, Bin Yu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Zhan Hua *Department of General Surgery, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Shan Wu *Research Center for Translational Medicine, Cancer Stem Cell Institute, East Hospital, Tongji University School of Medicine, Shanghai, China.
Yulian Zhang *Department of Neurosurgery, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Xiuhong WangDepartment of Pathology, China-Japan Friendship Hospital, Beijing, China.
Ju CuiThe Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Yunxuan LiNHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Chengcheng YangNingbo First Hospital, Ningbo, China.
Min ZhaiInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Bo DengInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Bin YuSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Jian-Dong HuangSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Zai WangInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Jianjun ZhouResearch Center for Translational Medicine, Cancer Stem Cell Institute, East Hospital, Tongji University School of Medicine, Shanghai, China.
China-Japan Friendship Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNTongji University · CNUniversity of Hong Kong · HKNingbo First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Liver metastasis is one of the primary causes of death for the patients with pancreatic neuroendocrine tumors (PNETs). However, no curative therapy has been developed so far. Methods: The anti-tumor efficacy of a genetically engineered tumor-targeting Results: We demonstrated that YB1 showed significant anti-tumor efficacy as a monotherapy. Since YB1 cannot infect INR1G9 cells, its anti-tumor effect was possibly due to the modulation of the tumor immune microenvironment. Two inflammatory factors IFNγ and CCL2 were elevated in the liver after YB1 administration, but only IFNγ was found to be responsible for the anti-tumor effect. Liver-targeted expression of IFNγ caused the activation of macrophages and NK cells, and reproduced the therapeutic effect of YB1 on liver metastasis. Conclusion: We demonstrated that YB1 may exhibit anti-tumor effect mainly based on IFNγ induction. Targeted IFNγ therapy can replace YB1 for treating liver metastasis of PNETs.

Indexed as

liver metastasispancreatic neuroendocrine tumorSalmonella typhimuriumtargeted IFNγ therapyYB1

Identifiers

PMID38020179
PMCPMC10644712
OpenAlexW4388090249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.